Education sets the basis for an AI-driven future of oncology
The deployment of artificial intelligence could lead to substantial advances in cancer care, but collaborative efforts are needed to increase trust among end users
Liquid biopsies are quickly evolving beyond ctDNA, but technical challenges remain
Newly-presented studies highlight that insights into cancer can also be unlocked from circulating tumour cells, exosomal microRNA and cell-free RNA
Does artificial intelligence have a place in precision oncology?
Applications in artificial intelligence have the potential to transform precision oncology, but data quality and clinical validation of tools are still challenging
KRAS and TP53 may have a key role in the development of pancreatic cancer
Studies provide new insights into the driver landscape of these gastrointestinal tumours and show improved prediction of patient-specific outcomes.
Multi-gene ctDNA profiling effectively matches patients with advanced cancer to targeted therapies
In France, a nationwide programme aims to broaden access to the technology based on the positive results collected so far
Growing evidence supports the use of ctDNA as a biomarker in colon cancer
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
Performance data from AI tools show progress in oncology
Cancer imaging and identification of predictive biomarkers are the best performed tasks reported in studies presented at ESMO Congress 2023
Sinonasal cancer: whole-exome sequencing reveals potential therapeutic targets
Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments
NGS – a weapon in molecular pathology?
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed
A study reveals the clonal heterogeneity of de novo metastatic castration-sensitive prostate cancer
Findings suggest that analysis of multiple prostate diagnostic biopsy cores, in contrast to frequent practice, may help reduce tumour mischaracterisation and identify genetic alterations relevant to personalised treatment